Google
Trusted Resources: Community Center
Online support, community stories, financial assistance
Prothena Corporation PLC – Linkedin
Prothena Corporation plc is a clinical-stage neuroscience company focused on the discovery and development of novel therapies with the potential to fundamentally change the course of progressive, life-threatening diseases. Fueled by its deep scientific understanding built over decades of neuroscience research, Prothena is advancing a pipeline of therapeutic candidates for a number of indications and novel targets including Parkinson’s disease and other related synucleinopathies (prasinezumab – PRX002/RG7935) and ATTR amyloidosis (PRX004), as well as tau, Aβ (Amyloid beta) and TDP-43 where its scientific understanding of disease pathology can be leveraged.
myBinderRelated Content
-
Mackenzie BoedickerMackenzie Boedicker is Founder, Presiden...
-
Amyloidosis & the GI Tracthttp://amyloidosissupport.org/support_gr...
-
International Myeloma FoundationThe International Myeloma Foundation (IM...
-
All About hATTR Amyloidosis: Patient Experience and Action on Testing, Treatment and CareJoin the first program in this speci...
-
Present Troubles RacingPresent Troubles Racing is a non-profit ...
-
Mary O’DonnellMary O'Donnell is President/CEO at Amylo...
-
Prothena Reports Results From the Phase 3 VITAL Amyloidosis Study of NEOD001 (Birtamimab) in AL AmyloidosisProthena Corporation PLC, a clinical-sta...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences.
More information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
